Integra LifeSciences Holdings (IART) 2015年年度报告「NASDAQ」.pdf

1、INTEGRA LIMITS UNCERTAINTYFor InvestorsFor HospitalsFor SurgeonsFor Patients2015 Annual ReportTotal RevenuesSelected Financial Data:2015 Revenues by Geographic AreaUnited StatesEuropeRest of World2015 Revenues by SegmentSegment%of Total Revenues Key Product Areas 2015 RevenuesSpecialty Surgical Solu

2、tionsOrthopedics&Tissue Technologies66%34%Complete specialty surgical instrumentation for a broad range of specialities,including a market-leading product porfolio used in the neurosurgery operating suite and critical care unit.Unique combination of differentiated soft tissue repair and tissue regen

3、eration products,and small bone fixation and joint replacement solutions.$587 Million$296 MillionAbout IntegraRegion2015 Revenues$681 Million$103 Million$99 MillionOperating Cash FlowDiluted Earnings Per Share*Revised for accounting principle change for the medical device excise tax.Integra LifeScie

4、nces,a world leader in medical technology,is dedicated to limiting uncertainty for caregivers,so they can concentrate on providing the best patient care.Founded in 1989 and headquartered in Plainsboro,NJ Employs approximately 3,500 employees worldwide Traded on NASDAQ under IARTIntegra strives to gr

5、ow profitably through the Execute,Optimize and Accelerate Growth strategy,offering innovative solutions,including leading regenerative technologies,in specialty surgical solutions,orthopedics and tissue technologies.To Our Stockholders:Integra,a recognized leader in specialty surgical solutions,rege

6、nerative technologies and extremitysolutions,worldwide,is committed to bringing certainty to physicians and patients,when every movement andmoment counts.We develop solutions for the most pressing perioperative issues facing our customers,allowingthem to focus on what is ultimately most important he